Nasdaq pgen.

(NASDAQ: PGEN) Precigen currently has 248,919,096 outstanding shares. With Precigen stock trading at $1.16 per share, the total value of Precigen stock (market capitalization) is $288.75M . Precigen stock was originally listed at a price of $24.73 in Aug 8, 2013 .Jan 24, 2023 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ... GERMANTOWN, Md., March 1, 2022 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2021 financial results. “In 2021, Precigen was able to demonstrate significant progress in our …Precigen Inc (NASDAQ:PGEN) is a company dedicated to creating innovative gene and cell therapies to improve the lives of patients.In their latest updates, they have shared financial information ...NIO. 7.15. -1.65%. 46.35M. View today's Precigen Inc stock price and latest PGEN news and analysis. Create real-time notifications to follow any changes in the live stock price.

GERMANTOWN, Md., Oct. 9, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that leading science and technology company and existing shareholder Merck KGaA, Darmstadt, Germany, …

Find the latest historical data for Precigen, Inc. Common Stock (PGEN) at Nasdaq.com.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent ...

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent ...NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON ...Since publicly traded Precigen shares are worth a total of US$1.24b, it seems unlikely that this level of liabilities would be a major threat. However, we do think it is worth keeping an eye on ...Find the latest historical data for Precigen, Inc. Common Stock (PGEN) at Nasdaq.com.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...

Nasdaq Futures. 15511.25-27.25 (-0.18%). Dow Jones Futures. 34865.0074.00 (0.21 ... NASDAQ:PGEN · Buy Candidate. Precigen, Inc. Stock Price (Quote). NASDAQ Stock ...

Precigen (NASDAQ:PGEN), a Virginia-based biopharmaceutical company, focuses on advancing gene and cell therapies to improve patient outcomes for unmet medical needs. The company uses proprietary ...

Fiscal Q3 2023 ended 9/30/23. Get the latest Precigen Inc (PGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed …Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen Inc (NASDAQ:PGEN) is a company dedicated to creating innovative gene and cell therapies to improve the lives of patients.In their latest updates, they have shared financial information ...In January 2023, four company executives bought PGEN stock. The largest of those buys was from executive chairman (and former CEO) Randall Kirk. Kirk purchased 11,428,571 shares of PGEN stock for ...Mar 6, 2023 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Dec 4, 2023 · Over the past 30 days, the shares of Precigen Inc (NASDAQ:PGEN) have changed 11.21%. Short interest in the company has seen 16.25 million shares shorted with days to cover at 9.69. Wall Street analysts have a consensus price target for the stock at $9.00, which means that the shares’ value could jump 86.78% from current levels.

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Jan 24, 2023 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ... Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Aug 28, 2023 · Precigen ( NASDAQ: PGEN) is a clinical-stage biopharmaceutical firm focusing on next-generation gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases ...

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...

What You Need To Know About Precigen, Inc.'s (NASDAQ:PGEN) Investor Composition. Jan 8, 2022.... (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision ...Precigen, Inc. (NASDAQ:PGEN)’s third quarter results saw the firm post $13.4 million in revenue, which, when compared to the year ago quarter’s $3.3 million in sales marked a 406% annual growth.The Trade: Precigen, Inc. (NASDAQ:PGEN) Director Randal J Kirk bought a total of 11,428,571 shares at an average price of $1.75. To acquire these shares, it cost around $20 million .Is Precigen (NASDAQ:PGEN) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and company ...Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company.Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to …PGEN Latest Pre Market Trades. Select time range to see more trades: Pre-Market Time (ET) Pre-Market Price. Pre-Market Share Volume. 09:29:37. $2.24. 7. 09:27:22.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...

VinFast Auto Ltd. Ordinary Shares. NVIDIA Corporation Common Stock. $485.09 -8.46 -1.71%. Find the latest dividend history for Precigen, Inc. Common Stock (PGEN) at Nasdaq.com.

(NASDAQ: PGEN) Precigen's 52-week high was $2.29, and its 52-week low was $0.81. It is currently -49.3% from its 52-week high and 44.1% from its 52-week low. …

Nov 30, 2023 · The public float for PGEN is 128.23M, and currently, short sellers hold a 12.67% ratio of that floaft. The average trading volume of PGEN on November 30, 2023 was 1.32M shares. PGEN) stock’s latest price update. Precigen Inc (NASDAQ: PGEN) has experienced a rise in its stock price by 4.09 compared to its previous closing price of 1.10. Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...The Trade: Precigen, Inc. (NASDAQ:PGEN) Director Randal J Kirk bought a total of 11,428,571 shares at an average price of $1.75. To acquire these shares, it cost around $20 million .VinFast Auto Ltd. Ordinary Shares. NVIDIA Corporation Common Stock. $485.09 -8.46 -1.71%. Find the latest dividend history for Precigen, Inc. Common Stock (PGEN) at Nasdaq.com.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of novel gene and cell therapies, has developed a ground-breaking technology that enables the treatment of AML using targeted CAR-T therapy administered overnight right at the facility where a patient is being treated.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (NASDAQ:PGEN), a Virginia-based biopharmaceutical company, focuses on advancing gene and cell therapies to improve patient outcomes for unmet medical needs. The company uses proprietary ...Jun 6, 2023 · Precigen (NASDAQ:PGEN), a Virginia-based biopharmaceutical company, focuses on advancing gene and cell therapies to improve patient outcomes for unmet medical needs. The company uses proprietary ... Dec 4, 2023 · InvestorPlace.com writer Gabriel Osorio-Mazzilli identifies Precigen (NASDAQ:PGEN) as a stock to buy this week following updates about the firm’s flagship PRGN-2012 therapy, an immunotherapy ...

Precigen, Inc. (NASDAQ:PGEN Get Free Report) insider Donald P. Lehr sold 10,947 shares of the stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $1.64, for a total value of $17,953.08. Following the completion of the sale, the insider now owns 428...10 Jun, 2021, 16:05 ET. GERMANTOWN, Md ,, June 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell ...(NASDAQ: PGEN) Precigen currently has 248,919,096 outstanding shares. With Precigen stock trading at $1.16 per share, the total value of Precigen stock (market capitalization) is $288.75M . Precigen stock was originally listed at a price of $24.73 in Aug 8, 2013 .uk.finance.yahoo.com - October 21 at 1:30 PM. Precigen (NASDAQ:PGEN) Stock Passes Below Two Hundred Day Moving Average of $1.29. americanbankingnews.com - October 19 at 3:22 AM. While institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 37% ownership. Instagram:https://instagram. propane futures pricesnok'jaxxon gold chain reviewsnexgen stock Dec 4, 2023 · Precigen has generated $0.00 earnings per share over the last year. Earnings for Precigen are expected to grow in the coming year, from ($0.34) to ($0.28) per share. Precigen has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 4th, 2024 based off prior year's report dates. Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Precigen has ... aluminum stockszero commission forex broker Although most of the market cap awarded to synthetic-biology conglomerate Intrexon (PGEN-0.89%) is derived from its potential in healthcare, analysts are beginning to eye the potential for perhaps ... stock price international paper Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.The Trade: Precigen, Inc. (NASDAQ:PGEN) Director Randal J Kirk bought a total of 11,428,571 shares at an average price of $1.75. To acquire these shares, it cost around $20 million .